Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

Next Previous
Trial Profile

Multi-center, Blinded, Randomized, Parallel-group, Phase 3 Study With Aprocitentan in Subjects With Resistant Hypertension (RHT)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aprocitentan (Primary)
  • Indications Resistant hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms PRECISION
  • Sponsors Actelion Pharmaceuticals; Idorsia Pharmaceuticals

Most Recent Events

  • 01 Apr 2025 Results (N=82) assessing aprocitentan for the blood pressure in black individuals were published in the Hypertension.
  • 18 Nov 2024 Results of sub-group analysis assessing efficacy and safety of aprocitentan in patients with resistant hypertension on the triple combination with or without beta-blockers, presented at the American Heart Association Scientific Sessions 2024.
  • 11 Nov 2024 According to an Idorsia Pharmaceuticals Media Release, the data of this trial will be presented at the American Heart Association (AHA) annual Scientific Sessions 2024, taking place in Chicago, Illinois, November 16 to 18, 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top